Dr MAYEUR Didier

Fiche personne

Coordonnées

Centre Georges-François Leclerc
1 rue du Professeur Marion
BP 77980
21079 DIJON Cedex

03 80 73 75 06

Territoire

Bourgogne

Statut

Hospitalier

Affiliation

Centre Georges-François Leclerc (CGFL)

Recherche

Mots clés : Soins oncologiques de support SOS

Projets

Relation entre les caractéristiques sociodémographiques, la détresse psychologique, le soutien social et le fardeau symptomatique élevé chez les patientes atteintes d’un cancer du sein à récepteurs hormonaux positifs traitées par hormonothérapie

2021 - Porteur du projet : Dr MAMGUEM KAMGA Ariane - Partenaire : Dr DABAKUYO-YONLI Sandrine , Pr GUILLEMIN Francis , Dr MAYEUR Didier

Publications

Patritumab deruxtecan in HRHER2 advanced breast cancer: a phase 2 trial.

Pistilli B, Mosele F, Corcos N, Pierotti L, Pradat Y, Le Bescond L, Lacroix-Triki M, Nachabeh G, Alfaro A, Catelain C, Job B, Mami-Chouaib F, Badel S, Farace F, Oulhen M, Kannouche P, Tran DTN, Droin N, Vicier C, Frenel JS, D'Hondt V, Dalenc F, Bachelot T, Ducoulombier A, Benderra MA, Loirat D, Mayeur D, Deluche E, Deneuve J, Cheikh-Hussin R, Guyader P, Signolle N, Godefroy K, Talbot H, Vakalopoulou M, Christodoulidis S, Bernard E, Koudou Y, Sporchia A, Suto F, Li L, Sternberg DW, Michiels S, André F, Sellami D, Montagnac G

Nat Med. 2025 09 4;:

The management of cancer-associated thromboembolism: Proposals from the French multidisciplinary INNOVTE CAT Working Group.

Mahé I, Benhamou Y, Benmaziane A, Bertoletti L, Bichon V, Bozec C, Cohen A, Couturaud F, Debourdeau P, Dielenseger P, Douriez É, Elias A, Espitia O, Frère C, Gaboreau Y, Gendron P, Girard P, Hanon O, Idbaih A, Laporte S, Mayeur D, Moustafa F, Pernod G, Roy PM, Bugat MR, Schmidt J, Scotte F, Sevestre MA, Mismetti P, Sanchez O

Arch Cardiovasc Dis. 2025 08 28;:

Financial toxicity and socioeconomic impact of cancer in Europe.

Vancoppenolle J, Franzen N, Azarang L, Juslin T, Krini M, Lubbers T, Mattson J, Mayeur D, Menezes R, Schmitt J, Scotte F, Seoane López O, Skaali T, Ubels J, Schlander M, Retel V, van Harten WH,

ESMO Open. 2025 06 9;10(6):105293

Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.

Mahé I, Carrier M, Mayeur D, Chidiac J, Vicaut E, Falvo N, Sanchez O, Grange C, Monreal M, López-Núñez JJ, Otero-Candelera R, Le Gal G, Yeo E, Righini M, Robert-Ebadi H, Huisman MV, Klok FA, Westerweel P, Agnelli G, Becattini C, Bamias A, Syrigos K, Szmit S, Torbicki A, Verhamme P, Maraveyas A, Cohen AT, Ay C, Chapelle C, Meyer G, Couturaud F, Mismetti P, Girard P, Bertoletti L, Laporte S,

N Engl J Med. 2025 03 29;:

Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib.

Ladoire S, Kamga AM, Galland L, Reda M, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Talucier H, Jankowski C, Coutant C, Arnould L, Dabakuyo S

NPJ Breast Cancer. 2025 02 1;11(1):10

Emerging toxicities in oncology.

Mayeur D

Curr Opin Oncol. 2025 01 16;:

[Supportive oncology care, unconventional practices and integrative oncology: The need for clarification].

Träger S, Mayeur D, Poulain P, Perraudin F, Krakowski I

Bull Cancer. 2024 10 8;:

Real-world prevalence, treatment and survival of "high risk" early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry.

Ladoire S, Mamguem Kamga A, Galland L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie SM, Hennequin A, Jankowski C, Albuisson J, Nambot S, Coutant C, Arnould L, Reda M, Truntzer C, Dabakuyo S

Breast. 2024 08 28;78:103789

[Translation into French and republication of: "Treatment of cancer-associated venous thromboembolism in patients under palliative care"].

Debourdeau P, Sevestre MA, Bertoletti L, Mayeur D, Girard P, Scotté F, Sanchez O, Mahé I, ,

Rev Med Interne. 2024 06 21;:

[Translation into French and republication of: "Anticoagulant treatment of cancer-associated thromboembolism"].

Mahé I, Mayeur D, Couturaud F, Scotté F, Benhamou Y, Benmaziane A, Bertoletti L, Laporte S, Girard P, Mismetti P, Sanchez O,

Rev Med Interne. 2024 04 26;:

Unmet needs and barriers in venous thromboembolism education and awareness among people living with cancer: A global survey.

Potere N, Mahé I, Angchaisuksiri P, Cesarman-Maus G, Tan CW, Rashid A, AlGahtani FH, Imbalzano E, van Es N, Leader A, Olayemi E, Porreca E, Áinle FN, Okoye HC, Candeloro M, Mayeur D, Valerio L, Clark RC, Castellucci LA, Barco S, Di Nisio M,

J Thromb Haemost. 2024 04 4;:

Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.

Roussot N, Constantin G, Desmoulins I, Bergeron A, Arnould L, Beltjens F, Mayeur D, Kaderbhai C, Hennequin A, Jankowski C, Padeano MM, Costaz H, Jacinto S, Michel E, Amet A, Coutant C, Costa B, Jouannaud C, Deblock M, Levy C, Ferrero JM, Kerbrat P, Brain E, Mouret-Reynier MA, Coudert B, Bertaut A, Ladoire S

Eur J Cancer. 2024 03 26;202:114037

Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience.

Baude J, Niogret J, Jacob P, Bardet F, Desmoulins I, Zanetta S, Kaderbhai C, Galland L, Mayeur D, Delattre B, Cormier L, Ladoire S

Cancers (Basel). 2024 01 9;16(2):

Anticoagulant treatment of cancer-associated thromboembolism.

Mahé I, Mayeur D, Couturaud F, Scotté F, Benhamou Y, Benmaziane A, Bertoletti L, Laporte S, Girard P, Mismetti P, Sanchez O,

Arch Cardiovasc Dis. 2023 11 23;:

Care pathways for patients with cancer-associated thrombosis: From diagnosis to long-term follow-up.

Sevestre MA, Gaboreau Y, Douriez E, Bichon V, Bozec C, Gendron P, Mayeur D, Scotté F, Mahé I, Sanchez O,

Arch Cardiovasc Dis. 2023 11 23;:

Treatment of cancer-associated venous thromboembolism in patients under palliative care.

Debourdeau P, Sevestre MA, Bertoletti L, Mayeur D, Girard P, Scotté F, Sanchez O, Mahé I,

Arch Cardiovasc Dis. 2023 11 23;:

Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.

Ilie SM, Briot N, Constantin G, Roussot N, Ilie A, Bergeron A, Arnould L, Beltjens F, Desmoulin I, Mayeur D, Kaderbhai C, Hennequin A, Jankowski C, Padeano MM, Costaz H, Amet A, Coutant C, Coudert B, Bertaut A, Ladoire S

Breast Cancer. 2023 08 10;:

Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool.

Goedegebuur J, Abbel D, Accassat S, Achterberg WP, Akbari A, Arfuch VM, Baddeley E, Bax JJ, Becker D, Bergmeijer B, Bertoletti L, Blom JW, Calvetti A, Cannegieter SC, Castro L, Chavannes NH, Coma-Auli N, Couffignal C, Edwards A, Edwards M, Enggaard H, Font C, Gava A, Geersing GJ, Geijteman ECT, Greenley S, Gregory C, Gussekloo J, Hoffmann I, Højen AA, van den Hout WB, Huisman MV, Jacobsen S, Jagosh J, Johnson MJ, Jørgensen L, Juffermans CCM, Kempers EK, Konstantinides S, Kroder AF, Kruip MJHA, Lafaie L, Langendoen JW, Larsen TB, Lifford K, van der Linden YM, Mahé I, Maiorana L, Maraveyas A, Martens ESL, Mayeur D, van Mens TE, Mohr K, Mooijaart SP, Murtagh FEM, Nelson A, Nielsen PB, Ording AG, Ørskov M, Pearson M, Poenou G, Portielje JEA, Raczkiewicz D, Rasmussen K, Trinks-Roerdink E, Schippers I, Seddon K, Sexton K, Sivell S, Skjøth F, Søgaard M, Szmit S, Trompet S, Vassal P, Visser C, van Vliet LM, Wilson E, Klok FA, Noble SIR

Thromb Res. 2023 05 13;228:54-60

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer.

Galland L, Roussot N, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Reda M, Albuisson J, Arnould L, Boidot R, Truntzer C, Ghiringhelli F, Ladoire S

Cancers (Basel). 2023 02 18;15(4):

Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results.

Réda M, Fouquier A, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Coudert B, Bertaut A, Ladoire S

Breast. 2023 02 4;68:149-156

PROPERTY: study protocol for a randomized, double-blind, multicenter placebo-controlled trial assessing neurotoxicity in patients with metastatic gastrointestinal cancer taking PHYCOCARE® during oxaliplatin-based chemotherapy.

Le Gouill-Jaijarat C, Péréon Y, Leroy M, Lépine O, Loloum A, Peluchon C, Volteau C, Martineau AS, Korner S, Perrault C, Benmaziane A, Girot P, Petorin C, Perret C, Ligeza-Poisson C, Mayeur D, Flet L, Chiffoleau A, Poinas A, Bennouna J

Trials. 2023 01 20;24(1):50

Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.

Ballot E, Galland L, Mananet H, Boidot R, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S

Breast Cancer Res. 2022 11 18;24(1):80

Management of Cancer-Associated Thrombosis in France: A National Survey among Vascular Disease and Supportive Care Specialists.

Mahé I, Chapelle C, Plaisance L, Bertoletti L, Mismetti P, Mayeur D, Mahé G, Couturaud F,

Cancers (Basel). 2022 08 27;14(17):

Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study.

Mahé I, Agnelli G, Ay C, Bamias A, Becattini C, Carrier M, Chapelle C, Cohen AT, Girard P, Huisman MV, Klok FA, López-Núñez JJ, Maraveyas A, Mayeur D, Mir O, Monreal M, Righini M, Samama CM, Syrigos K, Szmit S, Torbicki A, Verhamme P, Vicaut E, Wang TF, Meyer G, Laporte S

Thromb Haemost. 2022 04;122(4):646-656

Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing.

Galland L, Ballot E, Mananet H, Boidot R, Lecuelle J, Albuisson J, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S

NPJ Breast Cancer. 2022 Mar 4;8(1):28

Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study.

Ladoire S, Rederstorff E, Goussot V, Parnalland S, Briot N, Ballot E, Truntzer C, Ayati S, Bengrine-Lefevre L, Bremaud N, Coudert B, Desmoulins I, Favier L, Fraisse C, Fumet JD, Hennequin A, Hervieu A, Ilie S, Kaderbhai C, Lagrange A, Martin N, Mazilu I, Mayeur D, Palmier R, Simonet-Lamm AL, Vincent J, Zanetta S, Arnould L, Coutant C, Bertaut A, Ghiringhelli F

Eur J Cancer. 2022 Feb 1;165:13-24

Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients.

Marouille AL, Petit E, Kaderbhaï C, Desmoulins I, Hennequin A, Mayeur D, Fumet JD, Ladoire S, Tharin Z, Ayati S, Ilie S, Royer B, Schmitt A

Pharmaceutics. 2021 Oct 16;13(10):

A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.

Zelek L, Debourdeau P, Bourgeois H, Wagner JP, Brocard F, Lefeuvre-Plesse C, Chauffert B, Leheurteur M, Bachet JB, Simon H, Mayeur D, Scotté F

Oncologist. 2021 10;26(10):e1870-e1879

Trastuzumab-emtansine induced pleural and pericardial effusions.

Lombardi J, Lory P, Martin N, Mayeur D, Combret S, Grandvuillemin A, Boulay C, Schmitt A

J Oncol Pharm Pract. 2021 May 18;:10781552211015772

Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study.

Ladoire S, Goussot V, Redersdorff E, Cueff A, Ballot E, Truntzer C, Ayati S, Bengrine-Lefevre L, Bremaud N, Coudert B, Desmoulins I, Favier L, Fraisse C, Fumet JD, Hanu R, Hennequin A, Hervieu A, Ilie S, Kaderbhai C, Lagrange A, Martin N, Mazilu I, Mayeur D, Palmier R, Simonet-Lamm AL, Vincent J, Zanetta S, Arnould L, Coutant C, Bertaut A, Ghiringhelli F

Eur J Cancer. 2021 Feb 27;148:359-370

Population Pharmacokinetics of Palbociclib in aReal-World Situation.

Royer B, Kaderbhaï C, Fumet JD, Hennequin A, Desmoulins I, Ladoire S, Ayati S, Mayeur D, Ilie S, Schmitt A

Pharmaceuticals (Basel). 2021 Feb 24;14(3):

The official French guidelines to protect patients with cancer against SARS-CoV-2 infection.

You B, Ravaud A, Canivet A, Ganem G, Giraud P, Guimbaud R, Kaluzinski L, Krakowski I, Mayeur D, Grellety T, Lotz JP

Lancet Oncol. 2020 05;21(5):619-621

[Breaking bad news in cancer: where do we stand?].

Mayeur D

Rev Prat. 2020 04;70(4):367-368

[SARS-CoV-2/COVID 19 Infection and Solid Cancers: Synthesis of Recommendations for Health Professionals].

Grellety T, Ravaud A, Canivet A, Ganem G, Giraud P, Guimbaud R, Kaluzinski L, Krakowski I, Mayeur D, Lotz JP, You B

Bull Cancer. 2020 04;107(4):400-402

French Recommendations on Strategies for Preventing and Treating Osteoporosis Induced by Adjuvant Breast Cancer Therapies.

Bouvard B, Confavreux CB, Briot K, Bonneterre J, Cormier C, Cortet B, Hannoun-Lévi JM, Hennequin C, Javier RM, Kerbrat P, Lespessailles E, Lesur A, Mayeur D, Paccou J, Trémollières F, Vieillard MH, Debiais F

Joint Bone Spine. 2019 Jul 25;:

[Antineoplastic drug induced nausea and vomiting: What is the clinical practice in 2018? An update of AFSOS clinical guidelines].

Jovenin N, Eche-Gass A, Chèze S, Launay-Vacher V, Mayeur D, Rey JB, Joly F, Krakowski I, Scotté F,

Bull Cancer. 2019 05;106(5):497-509

French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation.

Briot K, Paccou J, Beuzeboc P, Bonneterre J, Bouvard B, Confavreux CB, Cormier C, Cortet B, Hannoun-Lévi JM, Hennequin C, Javier RM, Lespessailles E, Mayeur D, Mongiat Artus P, Vieillard MH, Debiais F

Joint Bone Spine. 2019 01;86(1):21-28